Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Sawai Aims at Sales of ¥10 Billion for Lipitor Generic
November 30, 2011
- Products Manufactured by BVL of the US Recalled in Response to EMA Recommendation
November 30, 2011
- US FDA Accepts NDA for Potential MS Treatment Carfilzomib: Ono
November 30, 2011
- Shionogi to Implement Organizational Change to Boost Domestic Sales Strength
November 29, 2011
- Pfizer Japan Obtains Approval for Additional Indication for Deep Mycosis Drug Diflucan
November 29, 2011
- AZ to Bolster Its Top Position in Breast Cancer Area
November 29, 2011
- Paraplatin Approved for Breast Cancer: BMKK
November 29, 2011
- Chugai Pharmaceutical to Introduce iPad2 to All MRs and MAs from Mid-January
November 29, 2011
- Mitsubishi Tanabe, Alfresa Obtain Approval for Additional Indication for Sleep Disorder Treatment Modiodal
November 29, 2011
- Pfizer Japan Launches 20 Generics with 10 APIs
November 29, 2011
- Kyowa Pharmaceutical Industry to Launch 2 Generic Drugs Made in India in 2012
November 28, 2011
- Nexium Ranked No. 1 Both in HP, GP Markets: RepTrack Survey
November 28, 2011
- Novartis Files NDA for NVA237 for COPD in Japan
November 28, 2011
- M3 Survey Shows Doctors Want KOL Who Are “Easy to Understand” and Have “Extensive Experience”
November 28, 2011
- Iressa Approved for EGFR Mutation-Positive NSCLC: AZ
November 28, 2011
- Yakult Receives Approval for Changes to Dosage, Administration for Elplat as Post-Operative Therapy for Colorectal Cancer
November 28, 2011
- Chugai Pharmaceutical Obtains Approval for Additional Indication for Anticancer Agent Herceptin
November 28, 2011
- Additional Indication of Solar Keratosis Approved for Mochida Pharmaceutical's Beselna Cream
November 28, 2011
- 26 Major JPMA Member Companies Report Declines in Sales, Profits, with 8.8% Drop in Overseas Sales
November 25, 2011
- Takeda Files NDA for Fixed-Dose Combination of DPP-4 Alogliptin, Metformin with US FDA
November 25, 2011
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…